top of page

Phase I/II data for neoGAA in Pompe disease presented

Sanofi and its specialty care global business unit Sanofi Genzyme has presented data from NEO1, its Phase I/II clinical study evaluating the investigational novel enzyme replacement therapy neoGAA in 24 patients with late-onset Pompe disease.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page